The art of the deal captured top traffic honors this past week on MPO's website.
Pageviews peaked with DuPont's revelation of its deal to acquire Donatelle Plastics, a medical device contract manufacturer that specializes in design, development, and manufacture of medical components and devices. DuPont’s healthcare exposure includes Spectrum Plastics, a developer of medical device components, and Liveo, a developer of silicone solutions for healthcare applications. Acquiring Donatelle brings the complementary tech and capabilities of medical device injection molding, liquid silicone rubber (LSR) processing, precision machining, device assembly, and tool building.
Site-seeing runner up was top company mainstay Medtronic, which attracted cybervisitors by disclosing Vice President/Chief Financial Officer Karen Parkhill's impending resignation. She will remain in her position until Aug. 2, upon which time her duties will be assumed by Senior Vice President of Global Planning Gary Corona. Parkhill is leaving the company to accept a CFO role at HP Inc.
Product-related news rounded out the week's big five virtual visits. AliveCor and Alcon generated cyberwaves for their respective FDA approvals, the former for KAI 12L artificial intelligence (AI) technology and the Kardia 12L ECG system, and the latter for its Unity vitreoretinal cataract system (VCS) and Unity cataract system (CS). AliveCor's solution reportedly is the first in the world to use AI for spotting life-threatening cardiac conditions, including heart attacks, using a reduced leadset. Kardia 12L ECG is also (allegedly) the first AI-powered, handheld, 12-lead ECG system with a single-cable design. The VCS and CS systems are the first introductions to Alcon’s Unity portfolio. The company said the two new systems debut workflow efficiencies over its current Constellation vision system for vitreoretinal procedures and Centurion vision system with Active Sentry for cataract surgery.
Tandem Diabetes Care was no site sojourn slouch, enticing MPO loyalists by sharing real-world insights from a Tandem Mobi with Control-IQ user survey. Results showed 86% of participants reported being satisfied or very satisfied with Mobi, regardless of prior therapy. They also agreed that Mobi improved their quality of life.